Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Regulation FDA

NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half

  • Analysis

Executive Summary

CDER approved 23 new drugs in the first half of 2017, topping the 22 approved in all 2016; there are at least 18 products in CDER's pipeline with a user fee date this year.

You may also be interested in...



US FDA Likely To Shatter Novel Approval Record In 2018

With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.

Priority Review Designations In US: Third Quarter Spike Continues In 2017

Third quarter saw record total of 26 announcements for priority review designations; drop-off now likely.

Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count

The latest drug development news and US FDA highlights from our Performance Tracker.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Drug Review Regulation FDA
Latest Headlines

Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives

‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount

Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program

See All
UsernamePublicRestriction

Register

PS121054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By